Price Vera H
Department of Dermatology, University of California, San Francisco, CA, USA.
Semin Cutan Med Surg. 2006 Mar;25(1):56-9. doi: 10.1016/j.sder.2006.01.008.
The best outcome of current treatments of cicatricial alopecia is induction of a clinical remission with arrest of symptoms and signs, but the progression of hair loss may continue insidiously. Current treatments do not arrest the underlying disease process. A scalp biopsy is the first step in management. Selection of treatment described herein is guided by the histopathologic findings, including the type, location and extent of the predominant cellular inflammatory infiltrate, and clinical disease activity. Cicatricial alopecias with predominantly lymphocytic infiltrates are treated with immunomodulating agents, and those with predominantly neutrophilic infiltrates are treated with antimicrobial agents. Treatment selection may be challenging and requires flexibility, as histopathologic features frequently overlap, are not clear cut, or change over time. In the future, cellular and molecular biology studies will hopefully identify unique markers for the clinically distinct cicatricial alopecias and lead to better treatments and a cure.
瘢痕性秃发目前治疗的最佳结果是诱导临床缓解,症状和体征停止,但脱发可能仍在不知不觉中继续进展。目前的治疗方法无法阻止潜在的疾病进程。头皮活检是治疗的第一步。本文所述治疗方法的选择以组织病理学结果为指导,包括主要细胞炎性浸润的类型、位置和范围,以及临床疾病活动度。以淋巴细胞浸润为主的瘢痕性秃发用免疫调节剂治疗,以中性粒细胞浸润为主的瘢痕性秃发用抗菌药物治疗。治疗选择可能具有挑战性,需要灵活性,因为组织病理学特征经常重叠、不明确或随时间变化。未来,细胞和分子生物学研究有望为临床上不同的瘢痕性秃发识别出独特的标志物,并带来更好的治疗方法和治愈方案。